NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug

Nuvation Bio's stock is rising after an RBC Capital analyst highlighted the drug safusidenib for IDH1-mutant glioma.

Analyst Leonid Timashev sees a $3 billion opportunity for safusidenib in the brain cancer market.

Updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.